Supreme Court to Address Induced Infringement Claims in Generic ‘Skinny Label’ Drug Marketing Dispute

On January 16, 2026, the U.S. Supreme Court agreed to review a pivotal case concerning the scope of generic drug manufacturers’ communications and marketing practices, and whether such activities may constitute inducement of patent infringement under the Hatch-Waxman Act’s skinny labeling framework. The case, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., centers on the practice of “skinny labeling,” whereby generic drug applicants omit patented indications from their product labels to gain FDA approval without infringing method-of-use patents.

Under the Hatch-Waxman Act, generic drug companies obtain FDA approval by filing an Abbreviated New Drug Application (ANDA), which must include labeling identical to the reference listed drug and certifications regarding patents listed in the FDA’s Orange Book (21 U.S.C. § 355(j)). To avoid infringement litigation on patented method-of-use claims, generic applicants may submit a Section viii statement (21 U.S.C. § 355(j)(2)(A)(viii)) declaring that their product does not seek approval for patented uses. This results in a “skinny label” that excludes patented indications, allowing generics to enter the market earlier while respecting patent rights.

However, the Hatch-Waxman framework does not provide a safe harbor against induced infringement claims. Patent holders often allege that generic manufacturers induce infringement by promoting their products for omitted patented uses despite the skinny label. The legal dispute typically focuses on whether the patented use was sufficiently omitted from labeling and whether promotional activities encourage infringement.

The Supreme Court’s forthcoming decision will address these issues in the context of Hikma’s generic version of Amarin’s Vascepa (icosapent ethyl). Vascepa is FDA-approved for two indications: severe hypertriglyceridemia (SH), approved in 2012, and a cardiovascular risk reduction indication (CV), approved in 2019. Amarin listed method-of-use patents covering the CV indication in the Orange Book following the supplemental approval.

Hikma filed an ANDA in 2016 seeking approval for a generic Vascepa, submitting Section viii statements to omit the CV indication and market the generic solely for the SH indication. The FDA approved Hikma’s skinny label in 2020. Amarin then sued Hikma for induced infringement, alleging Hikma’s public statements—such as investor communications touting Vascepa sales without distinguishing between indications and a website listing the generic under the hypertriglyceridemia category with an AB rating—encouraged infringement of the CV patents.

The district court dismissed Amarin’s inducement claims, finding insufficient allegations. However, the Federal Circuit reversed, holding that Amarin’s allegations plausibly stated a claim for induced infringement based on the totality of Hikma’s marketing conduct.

Hikma petitioned the Supreme Court, arguing that the Federal Circuit’s permissive pleading standard undermines Section viii by exposing skinny label generics to inducement claims arising from routine market statements. The Solicitor General filed a brief supporting Hikma’s petition. The Supreme Court granted review to clarify the limits of permissible generic promotion and the application of inducement liability in skinny label contexts.

The Court’s ruling will focus on whether, at the pleading stage, certain generic marketing statements combined with a skinny label can constitute inducement of infringement of omitted patented uses. Importantly, the case involves post-launch conduct rather than pre-launch labeling decisions, which may limit the scope of the decision.

Given the procedural posture and factual context, the Supreme Court’s decision may not fully resolve the broader legal landscape surrounding Section viii skinny labeling and induced infringement claims. Instead, it is expected to provide more concrete guidance on permissible generic promotional activities and the pleading standards for inducement claims.

Industry stakeholders should anticipate continued litigation shaping the interplay between FDA regulatory requirements and patent enforcement in the generic drug space. The Section viii carve-out remains a vital statutory pathway for earlier generic entry, but the Hikma case underscores the ongoing challenges in balancing patent rights with generic competition.

McGuireWoods will continue monitoring developments at the intersection of FDA regulation and intellectual property law. For further inquiries, interested parties may contact the authors or members of the Life Sciences Industry Team.